Brown J, Peters V
TransPacific Renal Network, San Rafael, CA 94903, USA.
Adv Ren Replace Ther. 2000 Oct;7(4 Suppl 1):S95-9.
According to the Centers for Disease Control (CDC) Survey of Dialysis Associated Diseases, California, which includes Network 17 and 18, had one of the lowest hepatitis B vaccination rates in the country for 1994, 1995, and 1996. With 3 outbreaks of hepatitis B (HBV) in California in 1994, hepatitis B vaccination was chosen as a quality improvement project in both Network 17 and 18. With input from both Medical Review Boards and HCFA Region X, a project was formulated which focused on the improvement of the number of facilities which had hepatitis B vaccination rates which are greater than 50%. The overall purpose of both projects was to: (1) achieve access to preventative services for end-stage renal disease (ESRD) Medicare beneficiaries; (2) increase the number of ESRD patients in California who are vaccinated for HBV; (3) eliminate dialysis in California as an independent risk factor for contracting HBV; (4) decrease the number of ESRD facilities with HBV vaccination rates of 0%; and (5) increase the number of ESRD facilities with HBV vaccination rates greater than 50%. In 1998, both Network 17 and 18 denominators were adjusted to reflect the population which is eligible for vaccination. Because of historically low vaccination rate in California, the 1998 data collection sought to ascertain precise numbers for the ESRD patient population. Data were used from the 1996 and 1997 CDC Survey of Dialysis Associated Diseases from baseline measurements of HBV vaccination rates for all facilities in both Network 17 and 18. The CDC did not conduct a survey in 1998, however, Network 17 and 18 conducted a survey of dialysis associated diseases for all of California ESRD facilities. A data collection tool was designed to gather information on processes and outcomes in each facility. This allowed a continuous quality improvement (CQI)-based approach to analyze the problem, where tools like cause/effect and Pareto diagrams provided information on factors and issues affecting low HBV vaccination rates. Interventions were designed to target those specific factors. Interventions included creation of the "Hepatitis Booklet" (Network 18) and the "Hepatitis Resource Guide" (Network 17); mailing of the resource material to all providers (Network 18), and with vaccination rates less than 50% (Network 17); development of facility specific profiles; and policy statements by both Medical Review Boards on Hepatitis B Vaccination. The number of ESRD patients in California who are vaccinated for HBV increased to 53% or 11,412 patients of 21,617 eligible patients in both Networks. The number of ESRD patients in California who are vaccinated plus those in the process of receiving the series brought the California vaccination rate of 72% or 15,653 for 21,617 eligible patients in both Networks. The number of ESRD facilities in California with HBV vaccination rates of 0% decreased to 10 facilities in 1998, from 75 facilities in 1997, and 135 facilities in 1996. The number of ESRD facilities in California with HBV vaccination rates more than 50% increased to 175 facilities, from 87 facilities in 1997, and 52 in 1996. The number of patients developing antibodies post-vaccine was 62% (Network 18). Facilities in Network 17 with vaccination rates exceeding 50% who did not receive the Hepatitis B Resource Guide vaccinated 44% of all patients vaccinated or in progress in Network 17 in 1998. Facilities in Network 17 with vaccination rates less than 50% who did receive the Hepatitis B Resource Guide vaccinated 57% of all patients vaccinated or in progress in Network 17. For the first time, vaccination rates were collected on peritoneal dialysis (PD) patients. In Network 17, 51% of PD patients are vaccinated versus 59% of hemodialysis patients. In Network 18, 48% of PD patients are vaccinated versus 48% of hemodialysis patients. Resource material and feedback reports developed by both Networks facilitated improvements in Hepatitis B vaccination of ESRD patients in Ca
根据疾病控制中心(CDC)的透析相关疾病调查,包括第17和18网络的加利福尼亚州在1994年、1995年和1996年的乙肝疫苗接种率是全国最低的之一。1994年加利福尼亚州发生了3起乙肝(HBV)疫情,因此第17和18网络都选择将乙肝疫苗接种作为一个质量改进项目。在医学审查委员会和医疗保险与医疗补助服务中心第10地区办公室的共同参与下,制定了一个项目,该项目重点在于提高乙肝疫苗接种率超过50%的机构数量。这两个项目的总体目标是:(1)为终末期肾病(ESRD)医疗保险受益人提供预防服务;(2)增加加利福尼亚州接种HBV疫苗的ESRD患者数量;(3)消除加利福尼亚州透析作为感染HBV的独立风险因素;(4)减少乙肝疫苗接种率为0%的ESRD机构数量;(5)增加乙肝疫苗接种率超过50%的ESRD机构数量。1998年,第17和18网络的分母都进行了调整,以反映符合接种条件的人群。由于加利福尼亚州历史上疫苗接种率较低,1998年的数据收集旨在确定ESRD患者人群的确切数字。数据来自1996年和1997年CDC的透析相关疾病调查,作为第17和18网络所有机构乙肝疫苗接种率的基线测量值。CDC在1998年没有进行调查,然而,第17和18网络对加利福尼亚州所有ESRD机构进行了透析相关疾病调查。设计了一个数据收集工具,以收集每个机构的过程和结果信息。这使得能够采用基于持续质量改进(CQI)的方法来分析问题,因果图和帕累托图等工具提供了影响低乙肝疫苗接种率的因素和问题的信息。针对这些特定因素设计了干预措施。干预措施包括编写《肝炎手册》(第18网络)和《肝炎资源指南》(第17网络);将资源材料邮寄给所有提供者(第18网络),以及接种率低于50%的机构(第17网络);制定机构特定概况;以及两个医学审查委员会关于乙肝疫苗接种的政策声明。加利福尼亚州接种HBV疫苗的ESRD患者数量增加到53%,即21617名符合条件患者中的11412名患者。加利福尼亚州接种疫苗的ESRD患者数量加上正在接受全程接种的患者数量,使两个网络中21617名符合条件患者的加利福尼亚州疫苗接种率达到72%或15653名。加利福尼亚州乙肝疫苗接种率为0%的ESRD机构数量从1996年的135个、1997年的75个减少到1998年的10个。加利福尼亚州乙肝疫苗接种率超过50%的ESRD机构数量从1997年的87个、1996年的52个增加到175个。接种疫苗后产生抗体的患者数量为62%(第18网络)。1998年,第17网络中接种率超过50%但未收到《乙肝资源指南》的机构,其接种的患者占第17网络所有接种或正在接种患者的44%。第17网络中接种率低于50%但收到《乙肝资源指南》的机构,其接种的患者占第17网络所有接种或正在接种患者的57%。首次收集了腹膜透析(PD)患者的疫苗接种率。在第17网络中,51%的PD患者接种了疫苗,而血液透析患者的接种率为59%。在第18网络中,48%的PD患者接种了疫苗,血液透析患者的接种率为48%。两个网络编写的资源材料和反馈报告促进了加利福尼亚州ESRD患者乙肝疫苗接种情况的改善。